Bcl-2 expression in acute myelogenous leukemia: The relation to myeloid antigen expression and response to therapy in Iranian patients

Neoplasma

Volumn 52, Issue 2, 2005, Pages 109-114

  Daneshbod, Y ^a   Amirghofran, Z ^a,b   Tabei, S Z ^a,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute myelogenous leukemia; Bcl 2

Indexed keywords

CD11B ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; HEMOGLOBIN; MICROSOMAL AMINOPEPTIDASE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW; CANCER REGRESSION; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; GENE EXPRESSION; HEMATOPOIETIC CELL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; IRAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO ONCOGENE; SCHOOL CHILD; THROMBOCYTE COUNT;

EID: 17044421611     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. AMIRGHOFRAN Z, ZAKERINIA M, SHAMSEDDIN A. Significant association between expression of the CD11b surface molecule and favorable outcome for patients with acute myeloblastic leukemia. Int J Hematol 2001; 73: 502-506.
2. BENSI L, LONGO R, VECCHI A, MESSORA C, GARAGNANI L et al. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 1995; 80: 98-102.
3. BINCOLETTO C, SAAD ST, DA SILVA ES, QUEIROZ ML. Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia. Eur J Haematol 1999; 62: 38-42.
4. BRADSTOCK K, MATTHEWS J, BENSON E, PAGE F, BISHOP J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994; 84: 1220-1225.
5. BRADBURY DA, ZHU YM, RUSSELL NH. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma 1997; 24: 221-228.
6. CAMPOS L, GUYOTAT D, ARCHIMBAUD E, DEVAUX Y, TREILLE D et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989; 72: 161-166.
7. CAMPOS L, ROUAULT JP, SABIDO O, ORIOL P, ROUBI N et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to hemotherapy. Blood 1993; 81: 3091-3096.
8. CHEN Y, HE M, XIANG Z, WU Y, YUE B et al. The comprehensive evaluation on four indices of drug resistance in acute myeloid leukemia. J Tongji Med Univ 1999; 19: 194-197.
9. CREUTZIG U, HARBOTT J, SPERLING C, RITTER J, ZIMMERMANN M et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995; 86: 3097-3108.
10. DABROWSKA M, PIETRUCZUK M, KOSTECKA I, SUCHOWIERSKA M, KLOCZKO J et al. The rate of apoptosis and expression of Bcl-2 and Bax in leukocytes of acute myeloblastic leukemia patients. Neoplasma 2003; 50: 339-344.
11. DELIA D, AIELLO A, SOLIGO D, FONTANELLA E, MELANI C et al. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 79: 1291-1298.
12. DEBATIN KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004; 53: 153-159.
13. DIMITROULAKOS J, THAI S, WASFY GH, HEDLEY DW, MINDEN MD et al. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000; 40: 167-178.
14. GRIFFIN JD, DAVIS R, NELSON DA, DAVEY FR, MAYER RJ et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986; 68: 1232-1241.
15. ILLES A, KRENACS L, BORBENYI Z. Follicular lymphoma. Orv Hetil 2003; 144: 2253-2261.
16. JAATTELA M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746-2756.
17. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
18. KAUR P, KALLAKURY BS, SHEEHAN CE, FISHER HA, KAUFMAN RP Jr et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004; 128: 39-43.
19. KIRKIN V, JOOS S, ZORNIG M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249.
20. KORNBLAU SM, THALL PF, ESTROV Z, WALTERSCHEID M, PATEL S et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999; 5: 1758-1766.
21. LAURIA F, RASPADORI D, RONDELLI D, VENTURA MA, FIACCHINI M et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997; 11: 2075-2078.
22. LINJAWI A, KONTOGIANNEA M, HALWANI F, EDWARDES M, METERISSIAN S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004; 198: 83-90.
23. PAIETTA E, ANDERSEN J, YUNIS J, ROWE JM, CASSILETH PA et al. Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group. Br J Haematol 1998; 100: 265-272.
24. POMMIER Y, SORDET O, ANTONY S, HAYWARD RL, KOHN KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-2949.
25. PORWIT-MacDONALD A, IVORY K, WILKINSON S, WHEATLEY K, WONG L et al. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995; 9: 1191-1198.
26. ROSENFELD C, KANTARJIAN H. Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies. Leuk Lymphoma 2001; 41: 493-500.
27. SAHU GR, DAS BR. Prognostic significance of p53 and Bcl-2 in acute lymphoblastic leukemia. Oncol Rep 2002; 9: 1391-1398.
28. SCHWARZINGER I, VALENT P, KOLLER U, MAROSI C, SCHNEIDER B et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990; 8: 423-430.
29. SORENSON CM. Bcl-2 family members and disease. Biochim Biophys Acta 2004; 1644: 169-177.
30. STAMMLER G, SAUERBREY A, ZINTL F, VOLM M. Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia. Apoptosis 1997; 2: 377-383.
31. TOTHOVA E, FRICOVA M, STECOVA N, KAFKOVA A, ELBERTOVA A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 2002; 49: 141-144.
32. TSOPLOU P, KOURAKLIS-SYMEONIDIS A, THANOPOULOU E, ZIKOS P, ORPHANOS V et al. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia 1999; 13: 1554-1563.
33. VAN STIJN A, VAN DER POL MA, KOK A, BONTJE PM, ROEMEN GM et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003; 88: 497-508.
34. YUE B, CHEN Y, YU D, XIANG Z. Study on the relationship between the Bcl-2/Bax ratio and the growth types of leukemic cells and drug resistance in acute myelogenous leukemia. J Tongji Med Univ 1998; 18: 101-104.
35. ZHOU J, CHEN Y, LI C, LIU W. The protein expression of Bcl-2, Bax, Fas/Apo-1 in acute myeloid leukemia. J Tongji Med Univ 1998; 18: 42-45.